TY - JOUR
T1 - Effects of Isoprenaline on ventricular myocyte shortening and Ca2+ transport in the Zucker rat
AU - Sultan, Ahmed
AU - Qureshi, Muhammad Anwar
AU - Howarth, Frank Christopher
N1 - Publisher Copyright:
© 2022
PY - 2022/10/15
Y1 - 2022/10/15
N2 - Obesity is an important risk factor for diabetes mellitus (DM) which is a major global health problem. Electro-mechanical dysfunction has been extensively described in diabetic heart and cardiovascular complications are an important cause of mortality and morbidity in diabetic patients. Objectives: To examine the effects of Isoprenaline (ISO) in obesity and diabesity on ventricular myocyte shortening and Ca2+ transport in Zucker fatty (ZF), Zucker diabetic fatty (ZDF) in comparison to Zucker lean (ZL) rats. Methods: Myocyte shortening and intracellular Ca2+ were investigated with video imaging and fluorescence photometry, respectively. Results: The amplitude of Isoprenaline stimulated shortening was significantly (p < 0.05) decreased in ZDF and ZF compared to ZL myocytes. The amplitude of Isoprenaline stimulated Ca2+ transient was also significantly (p < 0.05) reduced in ZF compared to ZL and modestly reduced in ZDF compared to ZL myocytes. Mean Isoprenaline stimulated time to peak along with time to half relaxation of shortening were unchanged in ZDF and ZF compared to ZL myocytes. Mean Isoprenaline stimulated time to peak Ca2+ transient was significantly shortened in ZF compared to ZL myocytes. Time to half decay of the Ca2+ transient was considerably prolonged in ZDF compared to ZL myocytes. Amplitude of Isoprenaline stimulated caffeine-evoked Ca2+ transients were significantly reduced in ZDF and ZF in comparison to ZL myocytes. Conclusion: Isoprenaline was less effective at generating an increase in the amplitude of shortening in ZDF and ZF in comparison to ZL myocytes and defects in Ca2+ signaling, and in particular SR Ca2+ transport, might partly underlie these abnormalities.
AB - Obesity is an important risk factor for diabetes mellitus (DM) which is a major global health problem. Electro-mechanical dysfunction has been extensively described in diabetic heart and cardiovascular complications are an important cause of mortality and morbidity in diabetic patients. Objectives: To examine the effects of Isoprenaline (ISO) in obesity and diabesity on ventricular myocyte shortening and Ca2+ transport in Zucker fatty (ZF), Zucker diabetic fatty (ZDF) in comparison to Zucker lean (ZL) rats. Methods: Myocyte shortening and intracellular Ca2+ were investigated with video imaging and fluorescence photometry, respectively. Results: The amplitude of Isoprenaline stimulated shortening was significantly (p < 0.05) decreased in ZDF and ZF compared to ZL myocytes. The amplitude of Isoprenaline stimulated Ca2+ transient was also significantly (p < 0.05) reduced in ZF compared to ZL and modestly reduced in ZDF compared to ZL myocytes. Mean Isoprenaline stimulated time to peak along with time to half relaxation of shortening were unchanged in ZDF and ZF compared to ZL myocytes. Mean Isoprenaline stimulated time to peak Ca2+ transient was significantly shortened in ZF compared to ZL myocytes. Time to half decay of the Ca2+ transient was considerably prolonged in ZDF compared to ZL myocytes. Amplitude of Isoprenaline stimulated caffeine-evoked Ca2+ transients were significantly reduced in ZDF and ZF in comparison to ZL myocytes. Conclusion: Isoprenaline was less effective at generating an increase in the amplitude of shortening in ZDF and ZF in comparison to ZL myocytes and defects in Ca2+ signaling, and in particular SR Ca2+ transport, might partly underlie these abnormalities.
KW - Ca signaling
KW - Diabetes
KW - Isoprenaline
KW - Myocyte shortening
KW - Obesity
KW - Ventricular myocytes
KW - Zucker rat
UR - http://www.scopus.com/inward/record.url?scp=85138093910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138093910&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2022.175263
DO - 10.1016/j.ejphar.2022.175263
M3 - Article
C2 - 36100128
AN - SCOPUS:85138093910
SN - 0014-2999
VL - 933
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
M1 - 175263
ER -